
How Pharmacists Can Address Curiosity Surrounding Peptides
As patients and prescribers flood pharmacies with peptide questions, an expert explains how pharmacists can turn confusion into counseling.
Peptides are not new to pharmacy practice. Long before they became a social media wellness trend, pharmacists were dispensing peptide drugs such as oxytocin in labor and delivery and, more recently, glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and obesity.
Many patients asking about peptides have already found them online, labeled “research use only” and sold without a prescription. As federal regulators consider letting pharmacies compound certain peptides, Matt Martin, PharmD, BCSCP, vice president of clinical services at PCCA, says the goal is to bring the prescriber, patient, and pharmacist back together on care decisions.
“I think what they’re trying to accomplish in putting this policy forward [is to] provide a regulated pathway that brings back that triad of the prescriber and the patient and the pharmacist together to direct patient care and to have discussions about these things, as opposed to people just finding products [in] all these uncommon venues for prescription medications,” Martin told Drug Topics®.
READ MORE:
In this week’s episode of Over the Counter, we caught up with Martin to help get an understanding of the rapidly developing peptide oversight, whether from a Department of Health and Human Services (HHS) draft policy or a potential FDA decision somewhere down the line. Listen through as he breaks down what we know now and what could make questions behind the pharmacy counter evolve like never before.
Understanding the Evolving Federal Regulatory Landscape
The regulatory background surrounding peptide compounding has shifted dramatically in recent years. In late 2023, federal regulators placed over a dozen peptides into Category 2 for compounding guidance, restricting state-licensed 503A pharmacies from compounding them as active ingredients due to safety concerns and limited clinical data.1
A major turning point occurred when the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend 6 peptides, including BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon, for potential inclusion on the Section 503A Bulk Drug Substances List. Following that vote, HHS introduced a draft policy offering interim enforcement discretion for Section 503A compounding under strict conditions.1-3
Under this proposal, compounders must meet rigorous standards, including obtaining ingredients from registered manufacturers, securing valid Certificates of Analysis, adhering to single-active-ingredient rules, and submitting adverse event reports to MedWatch.3
However, legal experts caution that interim enforcement discretion does not equal formal legalization. Adding bulk drug substances to the official 503A list requires notice-and-comment rulemaking, which can take a year or longer. Furthermore, these 6 peptides were never listed on Category 1, keeping their legal status in transition. At the same time, medical leadership has expressed strong reservations.1-3
The American Medical Association House of Delegates adopted policy urging federal officials to rescind policies that ease restrictions on compounding unapproved synthetic peptides, citing patient safety risks and calling for strict regulatory enforcement alongside state pharmacy boards.4
Meanwhile, FDA has issued warning letters to online vendors selling products under research-use-only labels, making clear that website disclaimers do not shield unapproved drugs marketed for human use.5
Practical Guidance for Community Pharmacists and Patient Counseling
As wellness trends continue to drive public curiosity around peptides like CJC-1295 and Ipamorelin, community pharmacists find themselves on the front lines of patient education. Patients often encounter exaggerated claims on social media or through direct-to-consumer online sellers where product quality and dosing accuracy remain questionable.2
Pharmacists can add significant value by helping patients understand the difference between FDA-approved medications and investigational compounds, as well as distinguishing between traditional 503A patient-specific compounding and 503B outsourcing facilities.
For pharmacy practice, Martin emphasizes the importance of patience and rigorous compliance while federal policies are finalized. Pharmacies must monitor state board rules, evaluate vendor qualification standards, and verify pharmaceutical-grade sourcing.2
Another advisory committee meeting scheduled before February 2027 will evaluate 5 additional peptides, including GHK-Cu, Melanotan II, Cathelicidin LL-37, dihexa acetate, and PEG-MGF. Rather than viewing peptides as broad universal treatments, Martin suggests treating them as prospective clinical tools tailored to individual care, ensuring that the prescriber, patient, and pharmacist remain aligned in clinical decision-making.1,2
Stay tuned for weekly podcast episodes of Over the Counter powered by Drug Topics. Check out our most recent episode with
REFERENCES
1. Snow CD, Palmer KL. FDA’s pep(tide) rally! what compounders and industry need to know (post 1 of 2). FDA Law Blog. April 21, 2026. Accessed November 19, 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
2. Barney M. The rise of peptides: what community pharmacists should know. Lumistry. August 13, 2026. Accessed November 19, 2026. https://lumistry.com/blog/the-rise-of-peptides-what-community-pharmacists-should-know/
3. Harrison TA, Lewis CA. HHS announces interim enforcement discretion for section 503A compounding with certain peptide bulk drug substances. Venable. November 6, 2026. Accessed November 19, 2026. https://www.venable.com/insights/publications/2026/11/hhs-announces-interim-enforcement
4. AMA adopts new policies to protect patients and strengthen public health. American Medical Association. November 9, 2026. Accessed November 19, 2026. https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-protect-patients-and-strengthen-public
5. Kundi A, Cowley EM, Golden S, et al. RUO-ined: five peptide vendors learn that ‘research use only’ is not a legal strategy. ArentFox Schiff. October 15, 2026. Accessed November 19, 2026. https://www.afslaw.com/perspectives/alerts/ruo-ined-five-peptide-vendors-learn-research-use-only-not-legal-strategy
Related to this article








